Life
Briefing: FDA Moves Toward Allowing Injectable Peptide Compounding
Strategic angle: The FDA is reconsidering its stance on compounding pharmacies, potentially allowing the production of injectable peptides previously banned due to safety concerns.
editorial-staff
1 min read
Updated 10 days ago
The FDA is reportedly reassessing its position on compounding pharmacies, particularly concerning injectable peptides that were previously banned due to safety issues.
This reconsideration could lead to significant changes in how compounding pharmacies operate, potentially increasing the availability of these products.
Additionally, the ongoing war in Iran is impacting recruitment for clinical trials, which may complicate the landscape for new peptide therapies.